Teva
Manufacturing · Israel · 10K+ Employees
View Company Info for Free
Overview
Headquarters
124 Dvora Hanevi'a St, Tel Aviv, Tel Avi...Phone Number
+972 39148213Website
www.tevapharm.comRevenue
$17.3 BillionStock Symbol
TEVAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
2
1
About Teva
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is dedicated to addressing unmet patient needs by advancing scientific research, expanding access to quality medicines, and streamlining the delivery of treatments -from established generics to cutting-edge therapeutic solutions.Explore more
Teva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Teva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Teva, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Teva recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Teva launches new products
Funding: Get notified immidiatlly once Teva has new funding data
Congratulate Masked Content for being promoted to Masked Content at Teva
Check if Teva has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Teva had a recent Job posting/layoffs
Check out if Teva is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Teva as Masked Content
Find 3 more new buyers
Compare Similar Companies to Teva
Compare insights from companies similar to Teva, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Teva
$17.3B
10K+
Public
$99.3B
1901
BS
Brian SavageExecutive Vice President & Interim Chief Legal Officer
$72.2B
10K+
Public
-
1876
Hideyuki TozakiDirector, Research & Development & Chief Operating Officer, Oncology
$56.7B
10K+
Public
-
1996
DC
Daniela CastanedaImmunology Director, Commercial Operations & Chief of Staff
Company Profile Activity
Activity Insights
Teva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teva.
Teva financials insights
Gather financial insights about Teva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Multiple Rounds
$11.3B
2012
Multiple Rounds
$7.6B
2015
Debt
$2.4B
Debt
$33.8B
2016
Multiple Rounds
$28.1B
2018
Corporate Investment
$358M
Debt
$4.5B
2019
Debt
$2.3B
2026
Private Equity
$400M
Teva Tech Stack
A closer look at the technologies used by Teva
See more technologies
Most Recent Scoops
Earnings
reported net debt of $12.9 billion at the end of Q2 2026, with a net debt to EBITDA ratio of 2.8x (2.3x excluding the MLX acquisition), and remains on track to achieve its target of below 2x net debt to EBITDA by 2027.
Business Finance, Finance, Financing & Debt
Project
Teva has outlined a pipeline launch sequence targeting one new asset per year over the next five years, including Olanzapine LAI in 2026, Ecopipam in 2027, and DARI and additional assets through 2028 to 2030, with combined pipeline peak sales potential of over $10 billion.
Earnings
reported that its biosimilar portfolio has grown to 15 products in market with 14 more in the pipeline, with 2 out of 5 US biosimilar products ranked number one, and the company on track to exceed its $800 million biosimilar revenue target by 2027.
Pharmaceuticals
Project
Teva has announced that its DARI dual-action rescue inhaler study for asthma is fully enrolled with over 2,700 patients, with the final event forecast by end of 2026 and data presentation expected in the first half of 2027.
Pharmaceuticals, Clinical Operations
Earnings
Corporate Strategy, Finance, Financial Operations
Teva News & Media
Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14
Teva Pharmaceutical is set to list its ordinary shares on Sept. 14.Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsChristopher Stevo - Senior Vice President...Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.
The stock has a 100% buy rating from polled analysts, with some eye-catching price targets.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teva
Sign Up For FreeTo access detailed company insights
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is... Read More
